News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,026 Results
Type
Article (39721)
Company Profile (248)
Press Release (659057)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204204)
Career Advice (2008)
Deals (35423)
Drug Delivery (95)
Drug Development (81062)
Employer Resources (172)
FDA (16185)
Job Trends (14861)
News (345245)
Policy (32542)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49449)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16190)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11637)
BIOSECURE Act (19)
Biosimilars (109)
Biotechnology (176)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2258)
Cardiovascular disease (174)
Career advice (1677)
Career pathing (30)
CAR-T (151)
Cell therapy (423)
Cervical cancer (19)
Clinical research (65997)
Collaboration (833)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2591)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2207)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86637)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112475)
Executive appointments (722)
FDA (17449)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (709)
Government (4417)
Grass and pollen (4)
Guidances (67)
Healthcare (18823)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2733)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16509)
IRA (40)
Job creations (3632)
Job search strategy (1423)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7911)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13378)
Medtech (13383)
Mergers & acquisitions (19459)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6514)
Non-profit (4481)
Now hiring (39)
Obesity (364)
Opinion (205)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (234)
Patient recruitment (112)
Peanut (46)
People (57311)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20565)
Phase II (29061)
Phase III (21652)
Pipeline (1203)
Policy (139)
Postmarket research (2564)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (378)
Real estate (5909)
Recruiting (65)
Regulatory (22284)
Reports (46)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (140)
Last 7 days (897)
Last 30 days (2623)
Last 365 days (32709)
2025 (10738)
2024 (35229)
2023 (40083)
2022 (51199)
2021 (55725)
2020 (54091)
2019 (46554)
2018 (35026)
2017 (32115)
2016 (31487)
2015 (37558)
2014 (31323)
2013 (26352)
2012 (28580)
2011 (29272)
2010 (27337)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37882)
Australia (6185)
California (6134)
Canada (2017)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81303)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4571)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1747)
North Carolina (967)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1097)
South Carolina (23)
South Dakota (1)
Southern California (2303)
Tennessee (101)
Texas (907)
United States (23130)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (551)
West Virginia (3)
Wisconsin (54)
699,026 Results for "biocon inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
March 7, 2025
·
6 min read
Press Releases
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
April 16, 2025
·
7 min read
Press Releases
Biocon Biologics Announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
April 10, 2025
·
8 min read
Press Releases
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
February 24, 2025
·
8 min read
Press Releases
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
March 10, 2025
·
7 min read
Press Releases
Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
4 min read
Press Releases
U.S. FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 Biosimilar to J&J’s Stelara® (Ustekinumab)
December 2, 2024
·
1 min read
Pharm Country
Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara®
Biocon Biologics Ltd (BBL) announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.
February 29, 2024
·
5 min read
Pharm Country
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
Biocon Biologics Ltd today announced that the U.S. Food and Drug Administration (US FDA) has approved the Company’s first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).
May 21, 2024
·
8 min read
Press Releases
Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
September 25, 2024
·
6 min read
1 of 69,903
Next
